Clearance of Hepatitis C Virus (HCV) Is Associated With Improved Outcomes in HCV-Associated Lymphoma.

MedStar author(s):
Citation: Clinical lymphoma, myeloma & leukemia. 21(2):e185-e193, 2021 02.PMID: 33132102Institution: MedStar Health Research Institute | MedStar Heart & Vascular Institute | MedStar Washington Hospital Center | Washington Cancer Institute | Washington Cancer Institute HDepartment: Medicine/Infectious Diseases | Medicine/Internal MedicineForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: *Antiviral Agents/tu [Therapeutic Use] | *Hepacivirus/ip [Isolation & Purification] | *Hepatitis C/dt [Drug Therapy] | *Lymphoma, Non-Hodgkin/mo [Mortality] | Adolescent | Adult | Aged | Aged, 80 and over | Female | Hepacivirus/ge [Genetics] | Hepatitis C/vi [Virology] | Humans | Lymphoma, Non-Hodgkin/th [Therapy] | Lymphoma, Non-Hodgkin/vi [Virology] | Male | Middle Aged | Progression-Free Survival | Retrospective Studies | RNA, Viral/ip [Isolation & Purification] | Young AdultYear: 2021ISSN:
  • 2152-2669
Name of journal: Clinical lymphoma, myeloma & leukemiaAbstract: BACKGROUND: Improved hepatitis C virus (HCV) clearance due to directly acting antiviral agents has led to remarkably improved outcomes of indolent HCV-associated non-Hodgkin lymphoma (NHL). The impact of directly acting antivirals on the outcomes of aggressive NHL is still under investigation. Characteristics of HCV-associated NHL in black patients are not well characterized. We report outcomes of HCV-associated NHL compared to their HCV-negative counterparts in a predominantly black population.CONCLUSION: HCV clearance is positively associated with lymphoma outcomes in black patients. Patients who clear HCV have noninferior outcomes to HCV- patients, while those who fail to clear HCV have significantly worse outcomes. Copyright (c) 2020 Elsevier Inc. All rights reserved.PATIENTS AND METHODS: Patients with lymphoma between January 2007 and December 2017 were retrospectively studied. Depending on presence or absence of HCV RNA, patients were grouped into HCV positive (HCV+) and HCV negative (HCV-) cohorts. Depending on virologic clearance (VC), HCV+ were classified into HCV+ with VC and HCV+ without VC. Overall response rate (ORR), complete response, overall survival (OS), and progression-free survival (PFS) of HCV+ patients with and without VC were compared to HCV- patients.RESULTS: Of 397 patients with lymphoma, 40 had HCV. Black comprised 90% of HCV+ patients. Diffuse large B-cell lymphoma was most frequent (47%) in the HCV+ group. HCV+ patients without VC had significantly worse OS and PFS compared to HCV- patients. There were no differences in ORR, complete response, PFS, and OS of HCV+ patients with VC and HCV- patients. These results were consistent in subgroups of diffuse large B-cell lymphoma and aggressive lymphoma.All authors: Adhikari T, Al-Shbool G, Baez-Sosa V, Desai SH, Fernandez S, Fishbein D, Hameed R, Malkovska V, Paku E, Stingo F, Vakiti AOriginally published: Clinical lymphoma, myeloma & leukemia. 2020 Oct 02Fiscal year: FY2021Fiscal year of original publication: FY2021Digital Object Identifier: Date added to catalog: 2020-12-29
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 33132102 Available 33132102

BACKGROUND: Improved hepatitis C virus (HCV) clearance due to directly acting antiviral agents has led to remarkably improved outcomes of indolent HCV-associated non-Hodgkin lymphoma (NHL). The impact of directly acting antivirals on the outcomes of aggressive NHL is still under investigation. Characteristics of HCV-associated NHL in black patients are not well characterized. We report outcomes of HCV-associated NHL compared to their HCV-negative counterparts in a predominantly black population.

CONCLUSION: HCV clearance is positively associated with lymphoma outcomes in black patients. Patients who clear HCV have noninferior outcomes to HCV- patients, while those who fail to clear HCV have significantly worse outcomes. Copyright (c) 2020 Elsevier Inc. All rights reserved.

PATIENTS AND METHODS: Patients with lymphoma between January 2007 and December 2017 were retrospectively studied. Depending on presence or absence of HCV RNA, patients were grouped into HCV positive (HCV+) and HCV negative (HCV-) cohorts. Depending on virologic clearance (VC), HCV+ were classified into HCV+ with VC and HCV+ without VC. Overall response rate (ORR), complete response, overall survival (OS), and progression-free survival (PFS) of HCV+ patients with and without VC were compared to HCV- patients.

RESULTS: Of 397 patients with lymphoma, 40 had HCV. Black comprised 90% of HCV+ patients. Diffuse large B-cell lymphoma was most frequent (47%) in the HCV+ group. HCV+ patients without VC had significantly worse OS and PFS compared to HCV- patients. There were no differences in ORR, complete response, PFS, and OS of HCV+ patients with VC and HCV- patients. These results were consistent in subgroups of diffuse large B-cell lymphoma and aggressive lymphoma.

English

Powered by Koha